IN COMING DECADES, INCREASED ACCESS TO IN VITRO FERTILIZATION THERAPIES WILL BE RESPONSIBLE FOR NEARLY 300 MILLION GLOBAL BIRTHS.
Today, one in 20 Japanese children is born via in vitro fertilization. In Norway, that number is one in 10. Almost all of these IVF births will begin as vitrified (frozen extremely quickly) cells and cryopreserved at -190 degrees Celsius.
Vitrification—a medical breakthrough only recently adopted for widespread use—enables reproductive cells to be viable over very long periods of time. It also contributes to the improvements of patient outcomes in a number of ways, including helping to eliminate multiple-birth pregnancies, facilitating genetic testing, and providing would-be parents more control over their reproductive planning. But vitrification of up to 300 million fertility cells requires faultless short- and long-term cryomanagement. It is this unique challenge and opportunity that led to TMRW building:
THE WORLD’S FIRST AUTOMATED CRYO AND SPECIMEN MANAGEMENT SYSTEM FOR IVF.
Our RFID-enabled digital chain of custody radically improves the identification, freezing and storage of reproductive cells and embryos—putting an end to the error-prone manual and analog methods that have gone unchanged since IVF was first used in animal husbandry more than fifty years ago. Developed in partnership with leading fertility doctors and embryologists, TMRW’s technology significantly reduces risk to the precious and fragile cells and tissues used in IVF.
Our automation eliminates 25% of the time required to perform manual tasks in the embryology lab, allowing embryologists to focus on the most skilled and technical aspects of their work.
TMRW provides a 100% digital chain of custody. This includes continuous local and remote electronic monitoring with integrated processes producing 17,000 daily health checks, which are used to constantly monitor, maintain and safeguard the integrity and security of the reproductive cells in our care. As requested by our physician partners, the TMRW platform is designed for both in-clinic and remote storage.
The TMRW team includes many of the world’s most celebrated pioneers in clinical medicine, reproductive biology, embryology, and cryogenic biobanking who have synthesized their collective knowledge, vision and experience in the development of the TMRW system.
Our founders have started both data science and medical firms, the most recent of which have been acquired for a combined exit value in excess of $1 billion.